타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 4개 · 임상 갱신 필요 4개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ||||
|---|---|---|---|---|
Overview Program | Keytruda (pembrolizumab) | Herceptin (trastuzumab) | Tecentriq (atezolizumab) | Enhertu (fam-trastuzumab deruxtecan-nxki) |
Overview Company | Merck | Roche / Genentech | Roche / Genentech | Daiichi Sankyo / AstraZeneca |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ADC |
Overview Target | PD-1 | HER2 | PD-L1 | HER2 |
Overview Indication | Multiple solid tumors | HER2+ breast cancer, HER2+ gastric/GEJ adenocarcinoma | NSCLC, SCLC, HCC, TNBC, urothelial carcinoma, and others | HER2-positive breast cancer (including regimen-specific first-line and early-stage indications); HER2-low/ultralow breast cancer, HER2-positive gastric cancer, HER2-mutant NSCLC and HER2-positive solid tumors: consult the current US label |
Overview Phase | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Content status | Curated Core | Curated Core | Curated Core | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved | FDA approved | FDA approved |
Positioning Key differentiator | Broad tumor-agnostic biomarker strategies (MSI-H, TMB) | novel bifunctional chelator (2E-C-NETA) for applications in 177 Lu-based TRT | novel agents have been approved in recent years (including systemic pembrolizumab, nogapendekin alfa inbakicept-pmln, N-803), | High DAR (~8), bystander effect, HER2-low activity |
Positioning Known limitation | Loss of antigen presentation (β2M, JAK1/2), alternate checkpoints (TIM-3, LAG-3), and immunosuppressive TME. | resistance to trastuzumab-based targeted therapy and limited intratumoral antibody penetration continue to restrict clinical outcomes | resistance to existing therapies | HER2 antigen loss/downregulation, payload efflux, and dose-limiting ILD/pneumonitis leading to discontinuation. |
Positioning Development positioning | — | — | — | Indication- and regimen-specific; includes 1L + pertuzumab in HER2-positive metastatic breast cancer |
Technology Payload | — | — | — | DXd (topo-I inhibitor) |
Technology Linker | — | — | — | Cleavable tetrapeptide |
MoA Mechanism | Pembrolizumab is an IgG4 humanized monoclonal antibody that binds PD-1 on T cells and blocks interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including antitumor response. | Trastuzumab binds domain IV of HER2, inhibiting ligand-independent HER2 signaling, mediating ADCC via Fcγ receptors, and inducing internalization/degradation of HER2. | Atezolizumab binds PD-L1 and blocks its interaction with PD-1 and B7.1 (CD80), enabling restoration of antitumor T-cell responses without direct PD-1 engagement on T cells. | Fam-trastuzumab deruxtecan is a HER2-directed antibody-drug conjugate: humanized anti-HER2 IgG1 linked via a cleavable tetrapeptide linker to DXd, a membrane-permeable topoisomerase I inhibitor. After binding HER2 on tumor cells, the conjugate is internalized; lysosomal proteases cleave the linker and release DXd, causing DNA damage and apoptosis. Released DXd can exert a bystander effect in neighboring cells. |
MoA Biomarker | PD-L1 CPS/TPS (tumor-specific), MSI-H/dMMR, TMB-H (≥10 mut/Mb), and tumor-type-specific biomarkers per label. | HER2 IHC 3+ or ISH amplified (ASCO/CAP guidelines). | PD-L1 IC/TC scoring in NSCLC and UC; tumor-type-specific thresholds. | HER2 expression (IHC/ISH per indication); higher systemic exposure associated with greater ILD incidence (FDA label §12.2). |
Toxicology Species | Cynomolgus monkey, Macaque, Mouse, Rat | Rat | Cynomolgus monkey, Mouse | Cynomolgus monkey, NHP, Rat, Hamster |
Toxicology Animal (cat.) | — | — | — | NHP |
Toxicology Major finding | Immune-related AEs | Cardiotoxicity (LVEF decline, CHF risk especially with anthracyclines); infusion reactions; myelosuppression in combos. | Immune-mediated pneumonitis, hepatitis, colitis, endocrinopathies. | ILD-like lung findings at high exposure |
Toxicology CRS | N/A | N/A | N/A | Minimal |
Toxicology NOAEL | — | — | — | 10 mg/kg |
Clinical Safety signal | Immune-related AEs | Cardiotoxicity (LVEF decline, CHF risk especially with anthracyclines); infusion reactions; myelosuppression in combos. | Immune-mediated pneumonitis, hepatitis, colitis, endocrinopathies. | ILD-like lung findings at high exposure |
Clinical Selected reported efficacy | — | — | — | ORR 87% |
Clinical Reported ORR | — | — | — | 87% vs 81% (THP) |
Clinical Reported PFS | — | — | — | 40.7 months vs 26.9 months (THP) |
Clinical Reported OS | — | — | — | Immature at the reported PFS analysis |
Clinical Result source | — | — | — | FDA label 2026, Table 28 — DESTINY-Breast09 (NCT04784715) |
Clinical Program phase | APPROVED | APPROVED | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts |
Clinical Trial ref | — | — | — | NCT04784715 |
Preclinical Animal (cat.) | — | Mouse, In vitro | — | Human, Mouse, In vitro |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 4개 · 임상 갱신 필요 4개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ||||
|---|---|---|---|---|
Overview Program | Keytruda (pembrolizumab) | Herceptin (trastuzumab) | Tecentriq (atezolizumab) | Enhertu (fam-trastuzumab deruxtecan-nxki) |
Overview Company | Merck | Roche / Genentech | Roche / Genentech | Daiichi Sankyo / AstraZeneca |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ADC |
Overview Target | PD-1 | HER2 | PD-L1 | HER2 |
Overview Indication | Multiple solid tumors | HER2+ breast cancer, HER2+ gastric/GEJ adenocarcinoma | NSCLC, SCLC, HCC, TNBC, urothelial carcinoma, and others | HER2-positive breast cancer (including regimen-specific first-line and early-stage indications); HER2-low/ultralow breast cancer, HER2-positive gastric cancer, HER2-mutant NSCLC and HER2-positive solid tumors: consult the current US label |
Overview Phase | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Content status | Curated Core | Curated Core | Curated Core | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved | FDA approved | FDA approved |
Positioning Key differentiator | Broad tumor-agnostic biomarker strategies (MSI-H, TMB) | novel bifunctional chelator (2E-C-NETA) for applications in 177 Lu-based TRT | novel agents have been approved in recent years (including systemic pembrolizumab, nogapendekin alfa inbakicept-pmln, N-803), | High DAR (~8), bystander effect, HER2-low activity |
Positioning Known limitation | Loss of antigen presentation (β2M, JAK1/2), alternate checkpoints (TIM-3, LAG-3), and immunosuppressive TME. | resistance to trastuzumab-based targeted therapy and limited intratumoral antibody penetration continue to restrict clinical outcomes | resistance to existing therapies | HER2 antigen loss/downregulation, payload efflux, and dose-limiting ILD/pneumonitis leading to discontinuation. |
Positioning Development positioning | — | — | — | Indication- and regimen-specific; includes 1L + pertuzumab in HER2-positive metastatic breast cancer |
Technology Payload | — | — | — | DXd (topo-I inhibitor) |
Technology Linker | — | — | — | Cleavable tetrapeptide |
MoA Mechanism | Pembrolizumab is an IgG4 humanized monoclonal antibody that binds PD-1 on T cells and blocks interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including antitumor response. | Trastuzumab binds domain IV of HER2, inhibiting ligand-independent HER2 signaling, mediating ADCC via Fcγ receptors, and inducing internalization/degradation of HER2. | Atezolizumab binds PD-L1 and blocks its interaction with PD-1 and B7.1 (CD80), enabling restoration of antitumor T-cell responses without direct PD-1 engagement on T cells. | Fam-trastuzumab deruxtecan is a HER2-directed antibody-drug conjugate: humanized anti-HER2 IgG1 linked via a cleavable tetrapeptide linker to DXd, a membrane-permeable topoisomerase I inhibitor. After binding HER2 on tumor cells, the conjugate is internalized; lysosomal proteases cleave the linker and release DXd, causing DNA damage and apoptosis. Released DXd can exert a bystander effect in neighboring cells. |
MoA Biomarker | PD-L1 CPS/TPS (tumor-specific), MSI-H/dMMR, TMB-H (≥10 mut/Mb), and tumor-type-specific biomarkers per label. | HER2 IHC 3+ or ISH amplified (ASCO/CAP guidelines). | PD-L1 IC/TC scoring in NSCLC and UC; tumor-type-specific thresholds. | HER2 expression (IHC/ISH per indication); higher systemic exposure associated with greater ILD incidence (FDA label §12.2). |
Toxicology Species | Cynomolgus monkey, Macaque, Mouse, Rat | Rat | Cynomolgus monkey, Mouse | Cynomolgus monkey, NHP, Rat, Hamster |
Toxicology Animal (cat.) | — | — | — | NHP |
Toxicology Major finding | Immune-related AEs | Cardiotoxicity (LVEF decline, CHF risk especially with anthracyclines); infusion reactions; myelosuppression in combos. | Immune-mediated pneumonitis, hepatitis, colitis, endocrinopathies. | ILD-like lung findings at high exposure |
Toxicology CRS | N/A | N/A | N/A | Minimal |
Toxicology NOAEL | — | — | — | 10 mg/kg |
Clinical Safety signal | Immune-related AEs | Cardiotoxicity (LVEF decline, CHF risk especially with anthracyclines); infusion reactions; myelosuppression in combos. | Immune-mediated pneumonitis, hepatitis, colitis, endocrinopathies. | ILD-like lung findings at high exposure |
Clinical Selected reported efficacy | — | — | — | ORR 87% |
Clinical Reported ORR | — | — | — | 87% vs 81% (THP) |
Clinical Reported PFS | — | — | — | 40.7 months vs 26.9 months (THP) |
Clinical Reported OS | — | — | — | Immature at the reported PFS analysis |
Clinical Result source | — | — | — | FDA label 2026, Table 28 — DESTINY-Breast09 (NCT04784715) |
Clinical Program phase | APPROVED | APPROVED | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts |
Clinical Trial ref | — | — | — | NCT04784715 |
Preclinical Animal (cat.) | — | Mouse, In vitro | — | Human, Mouse, In vitro |
추천 비교
추천 비교